An Open-label, Multi-Center, Phase IIIb Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia Who Are Eligible for "7+3" or "5+2" Chemotherapy
Midostaurin (PKC412), developed by Novartis Pharmaceuticals, targets FLT3 mutations in AML, a significant market segment with unmet needs. The combination of midostaurin with standard chemotherapy regimens (7+3 or 5+2) aims to improve patient outcomes in newly diagnosed FLT3-mutated AML. The study's completion and the anticipated results could strengthen Novartis's position in the oncology market, particularly against competitors like Astellas and Daiichi Sankyo, which also target FLT3 mutations. Successful outcomes may enhance market access and reimbursement opportunities, while potential adverse events could impact market perception and adoption.
Indication: Acute Myeloid Leukemia
Modality: small molecule
Target: Fms-like tyrosine kinase receptor (FLT3) mutations (ITD or TKD) in Acute Myeloid Leukemia (AML)
Sponsor: Novartis Pharmaceuticals
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 18, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Fms-like tyrosine kinase receptor (FLT3) mutations (ITD or TKD) in Acute Myeloid Leukemia (AML)
View original source fields
Condition raw: Acute Myeloid Leukemia
Condition normalized: Acute Myeloid Leukemia
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Fms-like tyrosine kinase receptor (FLT3) mutations (ITD or TKD) in Acute Myeloid Leukemia (AML)
Target normalized: Fms-like tyrosine kinase receptor (FLT3) mutations (ITD or TKD) in Acute Myeloid Leukemia (AML)